VIM and neoplasm: First, we crossed LSL-KrasG12D; Tp53fl/fl mice (KPV+/+) with vimentin knockout mice (KPV−/−) to demonstrate that KPV−/− mice have attenuated tumor growth and improved survival compared with KPV+/+ mice.